Last reviewed · How we verify
Squamous cell carcinoma — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Libtayo | CEMIPLIMAB | Regeneron Pharmaceuticals | PD-1 | 2018-01-01 | ||
| Blenoxane | BLEOMYCIN | Bristol-Myers Squibb | Cytoprotective Agent | Aspartyl/asparaginyl beta-hydroxylase | 1973-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Squamous cell carcinoma
- Bristol-Myers Squibb · 1 drug in Squamous cell carcinoma
- Regeneron Pharmaceuticals · 1 drug in Squamous cell carcinoma
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Squamous cell carcinoma:
- Squamous cell carcinoma treatment updates — RSS
- Squamous cell carcinoma treatment updates — Atom
- Squamous cell carcinoma treatment updates — JSON
Cite this brief
Drug Landscape (2026). Squamous cell carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/squamous-cell-carcinoma. Accessed 2026-06-10.
Related
- Squamous cell carcinoma full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing